One Wales Medicines interim decisions

Rituximab for interstitial lung disease (OW13): Last review date: February 2024

Adalimumab for paediatric intermediate, posterior and pan-uveitis (OW04): Last review date: November 2023

Arsenic trioxide for high risk acute promyelocytic leukaemia (OW06): Last review date: September 2023

Mepolizumab (Nucala®) for chronic eosinophilic pneumonia (OW15): Last review date: August 2023

Rituximab for pemphigus and pemphigoid (OW10): Last review date: July 2023

Sorafenib for acute myeloid leukaemia (AML) maintenance (OW18): Last review date: June 2023

Denosumab (Prolia®) for osteoporosis in men (OW07): Last review date: December 2022

1
2

Follow AWTTC: